🧬Biologics / Biosimilars
Large molecule drugs produced from living cells — antibodies, proteins, and biosimilars that target diseases with high precision.
Market Cap$4.2T
1D-1.49%
Companies1,421
Public Cos194
SECTOR MARKET CAP
$4.2T+13052.6%ALL
TOP COMPANIES
| # | Company | Country | Valuation | Ticker |
|---|---|---|---|---|
| 1 |  | United States | $851.4B | LLY |
| 2 |  | United States | $534.2B | JNJ |
| 3 |  | United States | $355.2B | ABBV |
| 4 |  | United Kingdom | $282.1B | AZN |
| 5 |  | Switzerland | $278.1B | NVS |
| 6 |  | Denmark | $201.3B | NVO |
| 7 |  | United States | $177.9B | AMGN |
| 8 |  | United States | $147.6B | PFE |
| 9 |  | France | $102.8B | SNY |
| 10 |  | Japan | $83.1B | 4519.T |
| 11 |  | United States | $74.6B | REGN |
| 12 |  | Belgium | $52.5B | UCB.VI |
| 13 |  | United States | $52.3B | TAK |
| 14 |  | China | $51.5B | 600276.SS |
| 15 |  | Netherlands | $49.0B | ARGX |
| 16 |  | South Korea | $46.6B | 207940.KS |
| 17 |  | Switzerland | $43.5B | LONN.SW |
| 18 |  | Germany | $43.2B | BAYN.DE |
| 19 |  | Australia | $41.6B | CSL.AX |
| 20 |  | Austria | $37.5B | SDZNY |